Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...
pharmaphorum6h
Pressure relieved on AZ as details of Chinese probe emerge
AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...
allAfrica.com on MSN11h
Kenya: Health Organisations Decry Poor Cancer Services, Urge Government Action
Healthcare organisations, including the Kenyan Network of Cancer Organisations (KENCO) and the NCD Alliance Kenya (NCDAK), have condemned the deteriorating health services for cancer patients, calling ...
‘With a cancer day care centre in my district, I can save on treatment and travel costs, save my mother’
As the cancer day care centre at AIIMS, Delhi, spills over, families hope decentralised treatment will cut costs, minimise ...